Bai H, Yu J, Jia S, et al. - Researchers assessed the status of TP53 mutations in cell-free DNA from patients with metastatic breast cancer (MBC) to evaluate disease characteristics and the prognostic role of different locations of the TP53 mutation site. They collected blood samples from a total of 187 patients diagnosed with MBC who were treated at the Department of Breast Oncology, Peking University Cancer Hospital between January 2013 and March 2020. The TP53 mutation spectra of circulating free DNA in these blood samples were investigated by using next-generation sequencing. This study’s findings demonstrate that TP53-mutated MBC patients had a significantly worse outcome than TP53 wild-type patients, especially those in HR+/HER2– and triple-negative breast cancer cohorts. As per the findings, of TP53-mutated patients with non-missense mutations in the DBD had worse breast cancer-related survival. There was a correlation between TP53 mutations and endocrine resistance.